Aravive — Investor Presentation (April 2021)
33 slides from Aravive's investor presentation, Apr 27, 2021
Slide 1: Corporate Presentation April 2021: Halting Disease Progression in its Tracks
Corporate Presentation April 2021 Halting Disease Progression in its Tracks ARAV (NASDAQ) © 2021 Aravive, Inc. 1 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements Forward Looking Statements © 2021 Aravive, Inc. 2 This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward- l
Slide 3: Experienced Management and Board of Directors
Experienced Management and Board of Directors Board of Directors Senior Management CEO Gail McIntyre, Ph.D., DABT CMO Reshma Rangwala, M.D., Ph.D. Chairman of the Board Fred Eshelman, Pharm D. Director Amato Giaccia, Ph.D. Director Michael Rogers Director Eric Zhang CFO Vinay Shah SVP of Data Scienc
Slide 4: AVB-500: First- & Potential Best-In-Class in Targeting GAS6/AXL Pathway
AVB-500: First- & Potential Best-In-Class in Targeting GAS6/AXL Pathway and Blocking the Signaling AVB-500 © 2021 Aravive, Inc. 4
Slide 5: GAS6/AXL Signaling Pathway: Key Driver of Cancer Growth
GAS6/AXL Signaling Pathway: Key Driver of Cancer Growth GAS6 and AXL are overexpressed in many cancers and associated with tumor growth, metastasis, drug resistance, and poor overall survival GAS6 is growth factor that regulates several biologic processes in cells through interaction with its recept
Slide 6: GAS6 & AXL Expression Associated with Poor Survival in Many Cancers
GAS6 & AXL Expression Associated with Poor Survival in Many Cancers “Clinically, the expression of GAS6 and TAM receptors always predicts poor prognosis” Wu G, et al. Molecular insights of Gas6/TAM in cancer development and therapy; Cell Death and Disease (2017) 8, e2700. AXL expressed in >70% of ov
Slide 7: AVB-500: Addresses Limitations of Other Therapies
As an engineered decoy receptor with 200-fold higher affinity for GAS6 versus natural GAS6/AXL interaction, AVB-500 provides potent & selective inhibition of this signaling pathway. Other approaches targeting GAS6/AXL signaling have drawbacks: Tyrosine Kinase Inhibitors lack selectivity, leading to
Slide 8: Clinical Pipeline
OVARIAN CANCER Platinum Resistant (AVB-500 + AstraZeneca’s Durvalumab) Forward-Looking Statements Clinical Pipeline Potential Opportunities for Expansion in Additional Indications and Drug Combinations Indication Preclinical Phase 1 Phase 3 Phase 2 Anti-CTGF AVB-500 IST at MDACC CANCER AND FIBROSIS
Slide 9: Lead Program: AVB-500 in Platinum Resistant Ovarian Cancer
Forward-Looking Statements Lead Program: AVB-500 in Platinum Resistant Ovarian Cancer (PROC); Patients Have Advanced Disease and High Mortality 5th LEADING CAUSE OF DEATH among women in the U.S. ~70% OF PATIENTS are diagnosed with advanced disease 50% 5-YEAR relative survival (9-12 months PROC) LESS
Slide 10: AVB-500 PROC: Phase 1a and 1b PK/PD Summary Data
AVB-500 PROC: Phase 1a and 1b PK/PD Summary Data AVB-500 q14 days Pegylated liposomal doxorubicin (PLD) 40 mg/m2 d1 of 28-day cycle; Paclitaxel (PAC) 80 mg/m2 day 1, day 8, day 15 of 28-day cycle; Maintenance dosing on AVB-500 monotherapy PROC = platinum-resistant ovarian cancer iDMC= Independent Da
Slide 11: Time on Treatment for AVB-500 + Paclitaxel Patients
Time on Treatment for AVB-500 + Paclitaxel Patients (10 and 15mg/kg groups) © 2021 Aravive, Inc. 11
Slide 12: AVB-500 / Paclitaxel Combination Clinical Activity in Subgroups
AVB-500 / Paclitaxel Combination Clinical Activity in Subgroups Note: AVB-500 + PAC and >MEC in bev naïve patients (n=7): mPFS 9.1 months and ORR of 71% Note: AVB-500 + PAC and <MEC: mPFS 2.8 months * Study ongoing so data can change; ** MEC = minimal efficacious concentration (13.8mg/L) For referen
Slide 13: sAXL/GAS6 Ratio Correlated with Response to AVB-500 + Chemo
sAXL/GAS6 Ratio Correlated with Response to AVB-500 + Chemo Serum levels of sAXL/GAS6 ratio (potential biomarker) correlated with response to AVB-500 + Chemo Building dataset to understand prognostic ability of biomarker May identify tumors that are dependent on the GAS6/AXL pathway Investigating in
Slide 14: Promising Responses in Patients > MEC with Poor Prognostic Indicators
Promising Responses in Patients > MEC with Poor Prognostic Indicators CLINICAL RESPONSE OF CHEMOTHERAPY IN PATIENTS WITH <3MO PLATINUM FREE INTERVAL** (N=21) CLINICAL RESPONSE OF CHEMOTHERAPY IN 3rd LINE AND 4th LINE*** (N=99) *All doses and both chemo cohorts; **Historical data from Cancer Chemothe
Slide 15: Dose Selected for AVB-500 Phase 3 Trial in PROC is 15mg/kg
Dose Selected for AVB-500 Phase 3 Trial in PROC is 15mg/kg 5/5 patients at 15mg/kg demonstrated clinical benefit: Consistent with hypothesis that trough levels are associated with clinical activity, all 5 evaluable patients in 15 mg/kg cohort achieved MEC by their first CT scan, following four doses
Slide 16: Strong Safety Profile of AVB-500
Strong Safety Profile of AVB-500 Safety report for trial AVB500-OC-002 generated by independent medical monitor concluded: “Based on a review of the safety data, no unexpected safety trends have been detected and the reported AE severity and frequency are consistent with expectations of the concomit
Slide 17: Competitive Advantages of AVB-500 in PROC
Competitive Advantages of AVB-500 in PROC: Favorable Safety Profile and Compelling Anti-Tumor Activity Favorable Safety Profile to Date NO DLTs like chemotherapies and ADCs NO dose reductions or discontinuations to manage toxicities NO toxicities that have been seen with ADCs: neutropenia, ocular to
Slide 18: Potentially More Favorable Benefit/Risk Profile vs Competitors
Potentially More Favorable Benefit/Risk Profile vs Competitors For illustrative purposes only, Data not generated from comparative study. Variation in study design including patient eligibility, response criteria, and assessment can affect outcomes and limit comparisons across studies. **Sources: Me
Slide 19: AVB-500 Phase 3 Adaptive Registrational Trial Design in PROC
FDA feedback: study could support full approval in PROC; no further preclinical or clinical studies required for BLA at this time Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Compare Efficacy and Tolerability of AVB-500 + PAC versus PAC (NCT04729608) AVB-500 Phase 3 Adaptive Regist
Slide 20: Second Indication: AVB-500 in Clear Cell Renal Cell Carcinoma
Forward-Looking Statements Second Indication: AVB-500 in Clear Cell Renal Cell Carcinoma; Patients Have Very Poor Survival Rates Renal Cell Carcinoma 15% 75k RESISTANCE To CHEMO OVER LESS THAN 5-YEAR relative survival for metastatic renal cancer NEW CASES expected in the U.S. in 2021 Is Common © 202
Slide 21: Strong Biological Rationale for AVB-500/Cabozantinib in ccRCC
Forward-Looking Statements Strong Biological Rationale for AVB-500/Cabozantinib in ccRCC GAS6/AXL in clear cell Renal Cell Carcinoma (ccRCC)1 AXL plays significant role in ccRCC invasion & metastasis AXL highly expressed in aggressive ccRCC tumors and associated with poor outcome GAS6/AXL signaling
Slide 22: Single Agent Activity in Highly Metastatic Renal Model (SN12L1)
Forward-Looking Statements Single Agent Activity in Highly Metastatic Renal Model (SN12L1) 5mg/kg AXL decoy administered twice/wk 10 mg/kg administered QOD Rankin et al, PNAS, September 16, 2014, vol. 111, no. 37, 13373–13378 Note: S6-1 and AVB-S6 are related AXL decoy proteins; both in S6 family Th
Slide 23: Synergistic Effect with AVB-500 & TKI Combo in TKI-Resistant Renal PDX
Forward-Looking Statements Synergistic Effect with AVB-500 & TKI Combo in TKI-Resistant Renal PDX AVB-500/Pazopanib Combination Significantly Reduced Growth Rate in TKI-Resistant Renal Patient-Derived Xenograft Models Xiao et al, Cancer Res 2019;79:5758–68; *note AVB-S6 is AVB-500 © 2021 Aravive, In
Slide 24: AVB-500/Cabozantinib Phase 1b / Phase 2 Trial Design in ccRCC
Forward-Looking Statements AVB-500/Cabozantinib Phase 1b / Phase 2 Trial Design in ccRCC Phase 1b Trial of AVB-500 in Combination with Cabozantinib Up to 18 patients; ability to increase/decrease dose based on tolerability, PK/PD Histologically confirmed metastatic ccRCC and patient has progressed o
Slide 25: Development Strategy: Conduct Additional Trials to Expand Pipeline
Preclinical data suggests that AVB-500 has potential in multiple combinations and indications: Combination trials with agents currently embedded as standard of care Earlier lines of therapy Multiple tumor types © 2021 Aravive, Inc. 25 Forward-Looking Statements Development Strategy: Conduct Addition
Slide 26: AVB-500: Large Market Opportunities in PROC, ccRCC & Other Indications
AVB-500: Large Market Opportunities in PROC, ccRCC & Other Indications 2L-4L platinum-resistant ovarian cancer (PROC), high grade serous patients 2L advanced/metastatic clear cell renal cell carcinoma (ccRCC) patients HER2 negative 2L+ patients (includes HR positive and TNBC) Exocrine (adenocarcinom
Slide 27: Strategic Collaboration with WuXi Biologics for Bispecific Antibodies
Forward-Looking Statements Strategic Collaboration with WuXi Biologics for High-Affinity Bispecific Antibodies Objective is to identify/develop novel, high-affinity bispecific antibodies against CCN2, also known as connective tissue growth factor (CTGF), targeting cancer/fibrosis using WuXiBody™ pla
Slide 28: 3D Medicines Collaboration to Develop/Commercialize AVB-500 in China
Forward-Looking Statements 3D Medicines Collaboration to Develop/Commercialize AVB-500 in China for Oncology Indications Exclusive collaboration and license agreement for development & commercialization of AVB-500 across all oncology indications in mainland China, Hong Kong, Macau, and Taiwan (Great
Slide 29: Financial Summary: Solid Financial Position
Forward-Looking Statements Financial Summary: Solid Financial Position Shares outstanding – 19.7 million* Cash and cash equivalents as of 12/31/20 – $60.5 million (Does not include approximately $21 million investment from Eshelman Ventures in Q1’2021) No debt Cash runway expected to fund current op
Slide 30: Aravive Top Shareholders
Aravive Top Shareholders Insiders, Institutional Shareholders Make Up approx. 70% of Our Outstanding Shares * As per SEC filings – 13D, 13F, 13G, Forms 3 and Form 4, Proxy ** As of 12/31/2020, adjusted for Eshelman Ventures investment in Feb-21 © 2021 Aravive, Inc. 30
Slide 31: Upcoming Key Milestones Advancing Our Clinical Development Program
Forward-Looking Statements Upcoming Key Milestones Advancing Our Clinical Development Program Q3’2021 – Anticipate completion of enrollment in Phase 1b ccRCC trial Q4’2021 – Anticipate initiation of Phase 2 ccRCC trial Q1’2022 – Anticipate interim analysis for Phase 3 PROC trial 2021 and beyond: Dat
Slide 32: Focused on difficult-to-treat cancers
Focused on difficult-to-treat cancers: AVB-500 lead indication; advanced stage ovarian cancer AVB-500 targets and inhibits GAS6/AXL signaling which is associated with tumor growth, metastasis, drug resistance, and poor patient survival AVB-500 is a differentiated innovative approach that addresses t
Slide 33: Thank you!
Thank you! Halting Disease Progression in its Tracks © 2021 Aravive, Inc. 33